-
艾媒报告|2020H1后疫时代全球呼吸机等医疗器械产品监测及企业案例报告
本报告研究涉及企业/品牌/案例:美敦力,GE医疗,迈瑞医疗,万孚生物,鱼跃医疗,乐普医疗,九安医疗;其他提及企业/品牌:冠昊生物,华海药业,金域医学,卫宁健康,新和成,健帆生物,费森尤斯医疗,嘉德诺,丹纳赫,史赛克,依视路陆逊梯卡,创业慧康,康恩贝,华北制药,通用电气,西门子,飞利浦,3M,绿盾,霍尼韦尔,保为康POWECOM,CM朝美,UVEX优唯斯,南丁,云南白药,维康WECAN,振德医疗,迪卡侬,锐步,速尔,爱康,KEEP,李宁,亿健,舒华,WALKINGPAD,英派斯,SKG,本博,倍轻松,南极人,凯仕乐,佳仁,茗振,小熊,璐瑶,攀高
2020年4月21日,全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询) 发布《2020H1后疫时代全球呼吸机等医疗器械产品监测及企业案例报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据,对全球范围内的医疗器械产品进行全面分析,并且报告聚焦于疫情问题下的呼吸机、额温枪等医疗器械,具体针对美敦力、GE医疗、迈瑞医疗、万孚生物、鱼跃医疗和乐普医疗等典型案例分析,对2020-2021年医疗器械行业发展进行趋势预判。特别在全球新冠肺炎疫情的严峻情势下,呼吸机、额温枪等医疗器械需求猛增,飞利浦、美敦力等西方医疗器械企业快速提高产量,以支持抗疫工作的迫切需求;同时,中国呼吸机等医疗器械企业的海外业务量有明显增长。艾媒咨询分析师认为,全球疫情势必带动医疗器械行业发展,但中国企业应当在保证自身产品质量的基础上抓住机遇,实现业务出海。
According to the data, the global medical device market has continued to increase in size since 2016, and the global medical device market is expected to reach USD 477.4 billion in 2020. Especially under the influence of the New Crown epidemic, the global demand for medical equipment such as ventilators and oxygen concentrators has increased dramatically. Overseas orders for Chinese medical device companies have skyrocketed. Within a certain period, the concept stocks of ventilator in the A-share market have risen. -
艾媒报告|2019-2022中国医疗器械市场大数据及标杆企业运行监测报告
本报告研究涉及企业/品牌/案例:安健科技,万东医疗,康达国际,上海联影,深圳迈瑞佳能,飞利浦,柯达,西门子,GE,安健,万东,通用电气,安科,东软丹纳赫,罗氏,利德曼,强生,科华,美康,九强,日立,迈克,东芝,中生,雅培,迪瑞,大基康明,金杏,致远,成武,长庚,康健,鑫乐,瑞琦,力因精准,积水,威高,拱东,三力,阳普医疗,BD,奥凯龙,重庆多泰,成都威力生,广州暨华,威海威高,山外山,金宝,尼普洛,百特,贝朗,费森透析,美敦力,鱼疗,理邦,尚荣医疗,英科医疗
相比于全球医疗器械市场,近三年中国医疗器械市场的结构已趋向优化但结构依然严重不平衡。早期中国医疗器械市场中,中低端产品占据了将近70%的比例,而高端产品仅占30%左右的比例,而国际医疗器械市场的结构为高端产品占55%,低端产品占45%。如新华医疗、迪安诊断、乐普医疗、鱼跃医疗等积极开拓高端市场及寻求出海发展。艾媒咨询分析师认为,受人工智能、物联网、5G等技术的影响,高端化、智能化和家庭化是中国医疗器械产业发展最为显著的三大趋势。特别是医疗大数据、高端医疗影像设备、家用医疗器械、智能便携式医疗设备等领域将会备受关注。
Compared with the global medical device market, the structure of China's medical device market has been optimized in the past three years, but the structure is still seriously unbalanced. In the early Chinese medical device market, low-end products accounted for nearly 70% of the proportion, while high-end products accounted for only about 30%, while the international medical device market accounted for 55% of high-end products and 45% of low-end products. Such as Xinhua Medical, Dean Diagnostics, Lepu Medical, Yuyue Medical, etc. actively explore the high-end market and seek to develop. iiMedia Research analysts believe that high-end, intelligent and family-oriented are the three most significant trends in the development of China's medical device industry due to the impact of artificial intelligence, Internet of Things, 5G and other technologies. In particular, medical big data, high-end medical imaging equipment, home medical equipment, smart portable medical equipment and other fields will be of great concern. -
艾媒报告 |2019中国按摩椅产业及共享按摩椅市场分析报告
本报告研究涉及企业/品牌/案例:京东,傲胜,荣泰健康,奥佳华,V3 group,云享云,小摩兽,码上按摩,恒林椅业,INGREM英格瑞玛,头等舱,爽蛙,尚铭电器,东方神,荣康,奥佳华,荣泰健康,豪中豪,乐金健康,康忆安,永禾康,本博,乐尔康,南极人,佳仁,茗振,QTQ,志高,乐摩吧,摩摩哒,爽客,码客街,头等舱互联奇拉,久工实业
中国老年人数量增长、亚健康人群超75.0%,具有养生需求的人群利好按摩椅市场的发展。2018年,中国按摩椅相关企业获投资金额2.6亿元,平均每笔按摩椅投资额超过5000万元。具体到两大电商销售渠道,按摩椅在天猫商城的月销售千笔以上的单品均价为3158.9元,京东商城热销前十的单品均价为6529.8元。在按摩市场细分企业中,2018荣泰健康、奥佳华第一大品类均为按摩椅,其营收占比分别为83.0%、42.2%。在按摩概念的广泛渗透下,共享按摩椅开始出现,目前主要应用场景在电影院、景区、地铁站、写字楼等。
The number of elderly people in China has increased, and the number of sub-healthy people has exceeded 75.0%. People who have health needs are in favor of the development of massage chair market. In 2018, China's massage chair-related enterprises received an investment of 260 million yuan, with an average investment of more than 50 million yuan per massage chair. Specifically to the two major e-commerce sales channels, the average price of massage chairs in Tianmao Mall is 3158.9 yuan per month, while the average price of the top ten items in Jingdong Mall is 6529.8 yuan. In the massage market segment enterprises, Rongtai Health and Ogawa's first major category in 2018 are massage chairs, whose revenue accounts for 83.0% and 42.2% respectively. Under the extensive penetration of massage concept, the sharing massage chair began to appear. At present, the main application scenarios are in cinemas, scenic spots, subway stations, office buildings, etc. -
艾媒报告|2019-2021中国口腔医院产业大数据及趋势分析报告
本报告研究涉及企业/品牌/案例:华西口腔医院,北京大学口腔医院,四川大学华西口腔医院,四川大学华西口腔医院,通策医疗,拜博口腔,瑞尔齿科,美维口腔,牙博士口腔,马泷齿科,佳美口腔,维尔口腔,美奥口腔,同步齿科,德伦口腔,爱牙,牙医管家,e看牙,牙e家,优益齿,共享牙医,牙医帮
截至2017年末,中国城市共有专业口腔医院535家,农村154家。艾媒咨询分析师认为,从专科医院领域的规模来看,在旺盛的医疗需求下,中国口腔市场还有很大的发展空间,特别是美颜经济兴起会进一步带动牙齿美白、矫正等业务发展。
从产业结构看,中国口腔行业主要包括牙种植、正畸、儿科、综合等项目,艾媒咨询分析师认为,目前中国口腔医疗正处于发展上升阶段,品牌开始获得一定认可,但发展主要集中在中低端市场,后续应当进一步向高端市场发力。从机构性质看,中国口腔医疗机构大致可分为综合性医院口腔科、公立专科口腔医院、连锁民营口腔医院及诊所和个体诊所四类。iiMedia Research(艾媒咨询)监测发现,首都医科大学附属口腔北京医院、泰康拜博等机构的排名靠前,受到更高认可度。
From the industrial structure, China's oral industry mainly includes dental implantation, orthodontics, pediatrics, comprehensive and other projects, Ai media consulting analysts believe that China's oral medicine is currently in the stage of development and rise, the brand began to get a certain recognition, but the development is mainly concentrated in the low-end market, the follow-up should further to the high-end market. From the institutional nature, China's oral medical institutions can be broadly divided into general hospital oral medicine, public specialized oral hospitals, chain private oral hospitals and clinics and individual clinics four categories. iiMedia Research monitoring found that the Capital Medical University affiliated oral Beijing Hospital, Taikang Baibo and other institutions ranked high, received a higher degree of recognition. -
艾媒报告 |2019中国基因测序产业研究和商业应用分析报告
本报告研究涉及企业/品牌/案例:Thermo Fisher(美),Illuminate(美),(瑞士),Stem cells(加),R&D(瑞士),华大基因,贝瑞基因,金城检验,美吉生物,恒创基因,基研生物,谱元科技,景杰生物,燃石生物,基迪奥生物,谷和信息,圣庭生物,天昊生物,诺禾致源,百迈克生物,思博奥科,赛莱拉,赛贝、北昊干细胞,达安基因,燃石医学、泛生子基因、世和基因,臻和生物,鹍远基因,23魔方,瀚海基因,百奥赛图,克睿基因,药明明码,裕策生物
随着基因测序的技术推进,基因测序开始应用于生物、侦查、无创产前检测和肿瘤治疗等场景中。技术的市场化应用吸引了全球资本方关注,iiMedia Research(艾媒咨询)数据显示,2018年全球医疗健康领域资本市场中,生物技术领域获得309件投资案共138亿元美元,领跑所有细分领域。中国生物技术科研研发实力厚积薄发,特别是科创板推动了基因测序市场的进一步升温,越来越多的生物创业公司在创业初期已获得高额融资。目前,中国已经基本形成了完整的上中下游产业链,但除了华大基因、贝瑞基因等少数头部企业,中国基因测序企业多数分布于产业链中下游,并且开始出现产品同质化等问题。艾媒咨询分析师认为,第二代测序技术的普及以及第三代测序技术的加紧研发将使得基因测序作为一个更加普遍的技术手段应用到不同场景之中,但目前仍然存在监管体系不够完善、道德伦理风险等问题。企业方面应当专注研究核心技术专利,通过人才储备和差异化竞争获得市场优势;行业和相关部门应当尽快完善行业规范管理体系,推动产业健康发展。
With the advancement of gene sequencing technology, gene sequencing began to be used in biological, detection, noninvasive prenatal testing and tumor treatment and other scenarios. The market-oriented application of technology has attracted global capital attention, with iiMedia Research leading all segments of the world in 309 investments in the global healthcare capital markets in 2018, with 309 investments, according to iiMedia Research. China's biotechnology research and development strength thick and thin hair, especially the science and technology board to promote the gene sequencing market further heating up, more and more bio-startup companies in the early stage of the start-up has been high financing. At present, China has basically formed a complete upstream and downstream industrial chain, but in addition to Huada gene, Berry gene and a few other head enterprises, Most of China's gene sequencing enterprises are distributed in the middle and lower reaches of the industrial chain, and began to appear product homogenization and other issues. Ai media consulting analysts believe that the popularity of second-generation sequencing technology and the third generation of sequencing technology will make gene sequencing as a more common technical means to apply to different scenarios, but there are still problems such as inadequate regulatory system, ethical risks. Enterprises should focus on researching core technology patents and gain market advantages through talent pool and differentiated competition, and industries and related departments should improve the industry standard management system as soon as possible to promote the healthy development of the industry. -
艾媒报告 |2019年中国生物医药产业发展及舆论焦点分析报告
本报告研究涉及企业/品牌包括:Takeda、GSK、Sanofi、Celgene、Novartis、宝洁、CVC Fund VII、Shire、诺华OTC、Bioverativ、Juno Therapeutics、AveXis、Impact Biomedicines、Tesaro、Ablynx、默克OTC、Recordati控股公司FIMEI、复星医药、海正药业、康弘药业、泰合健康、齐鲁制药、复宏汉霖、信达生物、张江生物、恒瑞医药、三生国健、嘉和生物、百奥泰、深圳龙瑞、天坛生物、华兰生物、博雅生物、上海莱士、卫光生物、辽宁成大、智飞生物、康泰生物、沃森生物、利德曼、交大昂立、华润双鹤、力生制药、海欣股份、联环药业、白云山、中源协和、普洛药业
随着生物医药技术不断突破,中国生物医药产业快速发展,2018年,单抗、血液制品、疫苗等生物医药相关领域多家头部上市企业营收均超亿元,实现同比增长。iiMedia Research(艾媒咨询)监测发现,生物医药产业网络言值指数为49.7,网民评价态度偏向正面,上海网民对生物医药产业的关注度最高。未来,随着中国生物医药行业上市公司数量增多,行业与企业间竞争将更加激烈。
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告